Drugs / Encochleated Amphotericin B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03196921 | Oct 2018 → Oct 2019 | cryptococcosis | Matinas BioPharma Nanotechnologies, Inc. | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-02-08 | Matinas BioPharma Nanotechnologies, Inc. | Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B matinasbiopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Encochleated Amphotericin B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03196921 ↗ |
| Route | Oral | “lipid-crystal nanoparticle formulation of amphotericin B; oral” NCT03196921 ↗ |